These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 24790002)
1. Improvement of the antitumor activity of poorly soluble sapacitabine (CS-682) by using Soluplus® as a surfactant. Obata T; Suzuki Y; Ogawa N; Kurimoto I; Yamamoto H; Furuno T; Sasaki T; Tanaka M Biol Pharm Bull; 2014; 37(5):802-7. PubMed ID: 24790002 [TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of a novel drug delivery: Soluplus Ding Y; Wang C; Wang Y; Xu Y; Zhao J; Gao M; Ding Y; Peng J; Li L Drug Dev Ind Pharm; 2018 Sep; 44(9):1409-1416. PubMed ID: 29718714 [TBL] [Abstract][Full Text] [Related]
3. Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines. Bernabeu E; Gonzalez L; Cagel M; Gergic EP; Moretton MA; Chiappetta DA Colloids Surf B Biointerfaces; 2016 Apr; 140():403-411. PubMed ID: 26780253 [TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678 [TBL] [Abstract][Full Text] [Related]
5. Soluplus/TPGS mixed micelles for dioscin delivery in cancer therapy. Zhao J; Xu Y; Wang C; Ding Y; Chen M; Wang Y; Peng J; Li L; Lv L Drug Dev Ind Pharm; 2017 Jul; 43(7):1197-1204. PubMed ID: 28300426 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757 [TBL] [Abstract][Full Text] [Related]
7. Improved anticancer activity of betulinic acid on breast cancer through a grafted copolymer-based micelles system. Qi X; Gao C; Yin C; Fan J; Wu X; Guo C Drug Deliv; 2021 Dec; 28(1):1962-1971. PubMed ID: 34565273 [TBL] [Abstract][Full Text] [Related]
8. Soluplus(®) micelles as a potential drug delivery system for reversal of resistant tumor. Jin X; Zhou B; Xue L; San W Biomed Pharmacother; 2015 Feb; 69():388-95. PubMed ID: 25661387 [TBL] [Abstract][Full Text] [Related]
9. A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells. Moretton MA; Bernabeu E; Grotz E; Gonzalez L; Zubillaga M; Chiappetta DA Eur J Pharm Biopharm; 2017 May; 114():305-316. PubMed ID: 28192249 [TBL] [Abstract][Full Text] [Related]
10. Sapacitabine in the treatment of acute myeloid leukemia. Norkin M; Richards AI Expert Rev Anticancer Ther; 2015; 15(11):1261-6. PubMed ID: 26523431 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of sapacitabine in treating patients with acute myeloid leukemia. Czemerska M; Robak T; Wierzbowska A Expert Opin Pharmacother; 2018 Nov; 19(16):1835-1839. PubMed ID: 30222471 [TBL] [Abstract][Full Text] [Related]
12. High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model. Wu M; Mazurchuk R; Chaudhary ND; Spernyak J; Veith J; Pera P; Greco W; Hoffman RM; Kobayashi T; Bernacki RJ Cancer Res; 2003 May; 63(10):2477-82. PubMed ID: 12750269 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Micellization Mechanism of an Amphipathic Graft Copolymer with Enhanced Solubility of Ipriflavone. Tanida S; Kurokawa T; Sato H; Kadota K; Tozuka Y Chem Pharm Bull (Tokyo); 2016; 64(1):68-72. PubMed ID: 26726747 [TBL] [Abstract][Full Text] [Related]
14. On the inherent properties of Soluplus and its application in ibuprofen solid dispersions generated by microwave-quench cooling technology. Shi NQ; Lai HW; Zhang Y; Feng B; Xiao X; Zhang HM; Li ZQ; Qi XR Pharm Dev Technol; 2018 Jul; 23(6):573-586. PubMed ID: 27824281 [TBL] [Abstract][Full Text] [Related]
15. Understanding the interaction between Soluplus® and biorelevant media components. Pinto JMO; Rengifo AFC; Mendes C; Leão AF; Parize AL; Stulzer HK Colloids Surf B Biointerfaces; 2020 Mar; 187():110673. PubMed ID: 31812452 [TBL] [Abstract][Full Text] [Related]
16. Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique. Ha ES; Baek IH; Cho W; Hwang SJ; Kim MS Chem Pharm Bull (Tokyo); 2014; 62(6):545-51. PubMed ID: 24881660 [TBL] [Abstract][Full Text] [Related]
17. Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. Linn M; Collnot EM; Djuric D; Hempel K; Fabian E; Kolter K; Lehr CM Eur J Pharm Sci; 2012 Feb; 45(3):336-43. PubMed ID: 22172603 [TBL] [Abstract][Full Text] [Related]
18. Sapacitabine for cancer. Liu X; Kantarjian H; Plunkett W Expert Opin Investig Drugs; 2012 Apr; 21(4):541-55. PubMed ID: 22329458 [TBL] [Abstract][Full Text] [Related]
19. Effect of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer on bioadhesion and release rate property of eplerenone pellets. Kendre PN; Chaudhari PD Drug Dev Ind Pharm; 2017 May; 43(5):751-761. PubMed ID: 27494543 [TBL] [Abstract][Full Text] [Related]
20. Improved oral absorption of dutasteride via Soluplus®-based supersaturable self-emulsifying drug delivery system (S-SEDDS). Lee DH; Yeom DW; Song YS; Cho HR; Choi YS; Kang MJ; Choi YW Int J Pharm; 2015 Jan; 478(1):341-347. PubMed ID: 25437113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]